AbbVie (ABBV) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
AbbVie (NYSE: ABBV) reported Q4 EPS of $2.79, $0.02 better than the analyst estimate of $2.77. Revenue for the quarter came in at $14.3 billion versus the consensus estimate of $14.01 billion.
GUIDANCE:
AbbVie sees FY2024 EPS of $11.05-$11.25, versus the consensus of $11.24.
For earnings history and earnings-related data on AbbVie (ABBV) click here.